The collective net worth of Korea’s 50 Richest on the 2024 Forbes list rose slightly to US$115 billion from $106 billion, amid the country’s global chipmaking ambitions. The complete list can be found at www.forbes.com/korea, as well as in the April/May issue of Forbes Asia and the May issue of Forb
It has been revealed that the market capitalization of the domestic stock market surged by nearly 100 trillion won in the first quarter of this year.According to the corporate analysis firm Korea CXO Research Institute on April 16, the total market capitalization of 2,692 stocks, excluding preferred
Celltrion announced on April 11 that “Zymfentra” (the U.S. brand name for Remsima), the world’s first subcutaneous formulation of infliximab for the treatment of autoimmune diseases developed in-house, has completed its formulation patent registration with the United States Patent and Trademark Offi
Foreign investors are shedding their holdings in secondary stocks in each industry and concentrating on the top stocks. With the resurgence of confidence in the semiconductor sector, they are buying both the top and secondary stocks in the semiconductor industry, but their interest seems to be focus
Celltrion announced on March 25 that it has received a recommendation for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) for the full label of its Xolair (active ingredient: omalizumab) biosimilar “CT-P39.”The original
Celltrion announced on March 11 that it has completed the application process for U.S. Food and Drug Administration (FDA) approval of “CT-P39,” a biosimilar to the asthma and chronic idiopathic urticaria treatment XOLAIR. The company applied for product approval based on the results of a global Phas
Celltrion is expanding its market presence in Peru, a major Latin American country, by winning a series of successful public tenders.First of all, Truxima (rituximab) 500 mg won a tender held by the National Health Ministry of Peru (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud
Celltrion announced on Feb. 6 that Rani Therapeutics (Rani) in the United States has confirmed positive topline results in the Phase 1 clinical trial of oral ustekinumab (development name: RT-111). RT-111 is an oral formulation of Celltrion’s Stelara biosimilar, CT-P43, currently under development.I
The pharmaceutical patent disputes between domestic biosimilar companies and original pharmaceutical firms are escalating.According to industry sources on Jan. 31, Samsung Bioepis and Celltrion are embroiled in patent disputes with original pharmaceutical companies.Alexion Pharmaceuticals, a subsidi
Celltrion announced on Jan. 29 that it has completed its application to the U.S. Food and Drug Administration (FDA) for the approval of CT-P47, a biosimilar to the autoimmune disease treatment drug Actemra (ingredient name: tocilizumab). The application was based on the results of a global Phase 3 c
Celltrion announced on Jan. 24 that it has signed a memorandum of understanding with WuXi XDC, a China-based company specialized in Antibody-Drug Conjugates (ADC), for the development of new ADC therapeutics, and has commenced product development for Contract Development and Manufacturing Organizati
Celltrion Group has successfully sold the Asia-Pacific (APAC) “Primary Care” business rights, which it acquired from multinational pharmaceutical company Takeda Pharmaceuticals (hereafter Takeda) in 2020, after three years.On Jan. 18, Celltrion concluded a contract with Dong-A Pharmaceutical for the
Celltrion has launched an 80-mg dosage form of its biosimilar Yuflyma (adalimumab) for the treatment of autoimmune diseases in the United States.Celltrion said on Jan. 17 that 80 mg is the same high-concentration (100 mg/ml) formulation as the 40 mg version that became available in the United States
Chairman Seo Jung-jin of Celltrion Group has revealed plans to list the holding company, Celltrion Holdings, on the NASDAQ in the United States.According to the industry sources on Jan. 15, Chairman Seo, who owns 98.5% of Celltrion Holdings, announced these plans while speaking at the Korean Busines
Celltrion’s biosimilar products for the treatment of autoimmune diseases have successively won bids in major European countries.According to Celltrion on Jan. 12, Yuflyma (active ingredient: adalimumab) has successfully won a government bid in Italy. Yuflyma was awarded in the adalimumab government
During a press conference at the JP Morgan Healthcare Conference (JPMHC), the world’s largest pharmaceutical and biotech investment event, on Jan. 10 (local time), Celltrion Group Chairman Seo Jung-jin announced that the company plans to establish a healthcare investment fund worth 100 trillion won.
A research study revealed that the total market capitalization of all listed companies in South Korea has increased by nearly 500 trillion won over the past year. The top two companies in terms of market cap growth were Samsung Electronics and SK hynix, with the combined market cap of these two comp
The 42nd JP Morgan Healthcare Conference is set to take place from Jan. 8 to 11 in San Francisco, California, in the U.S. This annual event, held every January, is renowned as the world’s largest healthcare investment venue where major global pharmaceutical companies, emerging biotech firms, and pro
Celltrion Group revealed on Jan. 2 that it plans to divest the business rights, excluding domestic specialty pharmaceuticals, of the Primary Care sector in the Asia-Pacific region that it acquired from multinational pharmaceutical company Takeda Pharmaceutical in 2020. This split sale, which exclude
On Dec. 28, the integrated company Celltrion will be officially launched. Celltrion is taking steps to leap into a global big pharmaceutical firm by merging with Celltrion Healthcare, which is responsible for global distribution.Celltrion and Celltrion Healthcare announced on Dec. 27 that they are i